YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
[mrna Cancer Vaccine] wildpixel/iStock via Getty Images INVESTORS SHOULD KNOW: Personalized mRNA cancer vaccines are moving beyond their first major clinical success in melanoma into a broader test across harder-to-treat solid tumors. The…
[Ozempic Insulin injection pen] CR/iStock via Getty Images INVESTORS SHOULD KNOW: The obesity drug market is undergoing a structural shift, moving beyond the initial injectable GLP-1 franchise. Now, the industry is moving toward a broader…
TOKYO, August 26, 2026--(BUSINESS WIRE)--The first patient has been dosed in the TROPION-Urothelial04 phase 3 trial evaluating Datroway® (datopotamab deruxtecan) plus rilvegostomig or Datroway monotherapy versus current standard of care (d…
[mRNA or messenger RNA. The concept of mRNA vaccine. Innovative methods to treat virus. 3d render] Krot Studio INVESTORS SHOULD KNOW: A major Phase 3 trial win from Moderna (MRNA [https://seekingalpha.com/symbol/MRNA]) and Merck (MRK [http…
Investing.com - U.S. stock index futures pointed higher on Thursday, as investors digested fresh corporate earnings and deal news while continuing to assess the outlook for inflation and interest rates. By 06:19 ET (10:19 GMT), the Dow fut…
COM701 MAIA-ovarian trial progressing as planned with median progression-free survival data from the interim analysis expected by Q1 2027 Trial-in-progress poster on MAIA-ovarian presented at the ESMO Gynaecological Cancers Congress 2026,…
Major earnings expected before the bell on Monday include: * Tyson Foods (TSN [https://seekingalpha.com/symbol/TSN]) * Marriott International (MAR [https://seekingalpha.com/symbol/MAR]) * EchoStar Corporation (ECHO [https://seekingalpha.co…
Compugen (NASDAQ:CGEN) said it remains on track to report interim progression-free survival data in the first quarter of 2027 from its MAIA-ovarian study, as the clinical-stage immuno-oncology company outlined first-quarter 2026 results an…
Major earnings expected before the bell on Monday include: * Baidu (BIDU [https://seekingalpha.com/symbol/BIDU]) * iQIYI (IQ [https://seekingalpha.com/symbol/IQ]) * Ryanair Holdings plc (RYAAY [https://seekingalpha.com/symbol/RYAAY]) * Niu…
* Compugen (CGEN [https://seekingalpha.com/symbol/CGEN]) is scheduled to announce Q1 earnings results on Monday, May 18th, after market close. * The consensus EPS Estimate is -$0.08 [https://seekingalpha.com/symbol/CGEN/earnings/estimates]…
Quant rankings for the upcoming earnings calendar show strength concentrated across consumer discretionary, communication services, and financials, while weakness is more pronounced in information technology and select consumer-facing segm…
Despite a relatively light earnings calendar, the upcoming week still features a broad mix of major players across retail, technology, semiconductors, healthcare, industrials, and global shipping. Leading the week will be NVIDIA (NVDA [htt…
Janux Therapeutics, Inc. (JANX) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.5. This compares to a loss of $0.38 per share a year ago. These figures are adjusted for non-recurring it…
BioMarin Pharmaceutical (BMRN) came out with quarterly earnings of $0.76 per share, missing the Zacks Consensus Estimate of $0.94 per share. This compares to earnings of $1.13 per share a year ago. These figures are adjusted for non-recurr…
Compugen Ltd. (NASDAQ:CGEN) is among the 11 Fastest Growing Penny Stocks to Buy Right Now.Compugen Ltd. (CGEN) Reports Q4 Revenue of $67.3 Million vs. $1.5 Million Last Year On March 2, 2026, Compugen Ltd. (NASDAQ:CGEN) reported fourth-qua…
This article first appeared on GuruFocus. Cash Balance: $145.6 million as of December 31, 2025. Revenue (Q4 2025): $67.3 million. Revenue (Full Year 2025): $72.8 million. R&D Expenses (Q4 2025): $5.5 million. R&D Expenses (Full Year 2025):…
Strengthened financial position through a non-dilutive transaction with AstraZeneca, monetizing a small portion of rilvegostomig royalties and extending expected cash runway into 2029 Enhanced leadership team with Dr. Eran Ophir appointed…
Major earnings expected before the bell on Monday include: * Norwegian Cruise Line Holdings Ltd. (NCLH [https://seekingalpha.com/symbol/NCLH]) * Uniti Group (UNIT [https://seekingalpha.com/symbol/UNIT]) * The Progressive Corporation (PGR […
* Compugen (CGEN [https://seekingalpha.com/symbol/CGEN]) is scheduled to announce Q4 earnings results on Monday, March 2nd, before market open. The consensus EPS Estimate is $0.14 [https://seekingalpha.com/symbol/CGEN/earnings/estimates] (…
Kymera Therapeutics, Inc. (KYMR) came out with a quarterly loss of $0.97 per share versus the Zacks Consensus Estimate of a loss of $0.77. This compares to a loss of $0.88 per share a year ago. These figures are adjusted for non-recurring…
Acadia Pharmaceuticals (ACAD) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.12 per share. This compares to earnings of $0.17 per share a year ago. These figures are adjusted for non-recurri…
Non-dilutive strategic transaction expected to extend cash runway into 2029, to advance Compugen's innovative immuno-oncology pipeline and to reach potential key catalysts from internal and partnered programs Monetization includes an upfro…
This article first appeared on GuruFocus. Release Date: November 10, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Compugen Ltd (NASDAQ:CGEN) is pioneering in comp…
COM701 Phase 1 data presented at ESMO 2025 characterized patients who derived clinical benefit and informed the design of the ongoing MAIA-ovarian platform trial Enrolling patients in the U.S., Israel and France in the MAIA-ovarian platfor…
Major earnings expected before the bell on Monday include: * Organon & Co. (OGN [https://seekingalpha.com/symbol/OGN]) * Starwood Property Trust (STWD [https://seekingalpha.com/symbol/STWD]) * Tyson Foods (TSN [https://seekingalpha.com/sym…
Certara, Inc. (CERT) came out with quarterly earnings of $0.14 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.13 per share a year ago. These figures are adjusted for non-recurring items.…
Vertex Pharmaceuticals (VRTX) came out with quarterly earnings of $4.8 per share, beating the Zacks Consensus Estimate of $4.55 per share. This compares to earnings of $4.38 per share a year ago. These figures are adjusted for non-recurrin…
A confirmed objective response rate of 68.2% and a disease control rate of 95.5% was observed with Daiichi Sankyo and AstraZeneca’s DATROWAY in combination with rilvegostomig in previously untreated, cisplatin ineligible patients TROPION-U…
COMPUGEN LTD (NASDAQ:CGEN [https://www.chartmill.com/stock/quote/CGEN/profile]) MISSES REVENUE AND EPS ESTIMATES IN Q2 2025, SHARES DIP IN PREMARKET Compugen Ltd, a clinical-stage cancer immunotherapy company, reported its second-quarter 2…
* Compugen press release [https://seekingalpha.com/pr/20190642-compugen-reports-second-quarter-2025-results] (NASDAQ:CGEN [https://seekingalpha.com/symbol/CGEN]): Q2 GAAP EPS of -$0.08 misses by $0.01. * Revenue of $1.3M (-80.6% Y/Y) misse…
First patient dosed in MAIA-ovarian platform trial of COM701 maintenance therapy in patients with platinum sensitive ovarian cancer in July 2025 Pooled analysis from three previously reported Phase 1 trials of COM701 in platinum resistant…
Major earnings expected before the bell on Wednesday include: * The Walt Disney Company (DIS [https://seekingalpha.com/symbol/DIS]) * Shopify (SHOP [https://seekingalpha.com/symbol/SHOP]) * McDonald's Corporation (MCD [https://seekingalpha…
* Compugen (NASDAQ:CGEN [https://seekingalpha.com/symbol/CGEN]) is scheduled to announce Q2 earnings results on Wednesday, August 6th, before market open. * The consensus EPS Estimate is -$0.09 [https://seekingalpha.com/symbol/CGEN/earning…
Cash Balance: Approximately $103.3 million as of December 31, 2024. Revenue: $1.5 million for Q4 2024; $27.9 million for the full year 2024. R&D Expenses: $5.9 million for Q4 2024; $24.8 million for the full year 2024. G&A Expenses: $2.2 m…
Phase 3 trial evaluating rilvegostomig as monotherapy and in combination with AstraZeneca and Daiichi Sankyo's datopotamab deruxtecan in first-line nonsquamous non-small cell lung cancer Broadening the assessment of rilvegostomig reinforce…
Compugen Ltd. (NASDAQ:CGEN) Q4 2023 Earnings Call Transcript March 5, 2024 Compugen Ltd. beats earnings expectations. Reported EPS is $0.11, expectations were $0.1. CGEN isn't one of the 30 most popular stocks among hedge funds at the end…